Chongqing Hilan Pharmaceutical Co., Ltd.

Primary study objective: To study the pharmacokinetic characteristics of the test preparation loxoprofen sodium patch (specification: 100 mg/patch (10 cm×14 cm), produced by Chongqing Xi'an Pharmaceutical Co., Ltd.) and the reference preparation loxoprofen sodium patch (Lesong®, specification: 100 mg/patch (10 cm×14 cm); produced by LEAD CHEMICAL CO., LTD. HISAGANE PLANT) in healthy Chinese adult subjects after single percutaneous administration under fasting conditions, and to evaluate the bioequivalence of the two preparations. Secondary study objective: To study the adhesion and safety of the test preparation loxoprofen sodium patch (specification: 100 mg/patch (10 cm×14 cm)) and the reference preparation loxoprofen sodium patch (Lesong®, specification: 100 mg/patch (10 cm×14 cm)) in healthy Chinese adult subjects.

The main purpose of the study is to observe the pharmacokinetic characteristics of the test preparation crisaborole ointment [Specification: 2% (30 g: 0.6 g), produced by Chongqing Xi'an Pharmaceutical Co., Ltd.] and the reference preparation crisaborole ointment [trade name: Staquis®, specification: 2%, licensed by Anacor Pharmaceuticals, Inc., produced by Pharmacia and Upjohn Company LLC] in Chinese healthy subjects after single topical application under fasting conditions, estimate the pharmacokinetic parameters of the two preparations, and evaluate the bioequivalence between the two preparations. Secondary purpose of the study: to observe the safety of the test preparation and reference preparation of crisaborole ointment in healthy subjects.

Evaluation of the effectiveness and safety of Shugan Shunqi Pills in treating functional dyspepsia